Biovie Inc (BIVI NASDAQ) stock market data APIs
$1.9573
0.08(4.1%)
as of September 9, 2026
Try our APIs with
free plan!
Biovie Inc Financial Data Overview
Price chart is built with
Anychart
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism. It also develops Bezisterim, an investigational, novel, orally administered small molecule that is In Phase 3 clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2b clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
Prev. Close
1.9573
Open
2.035
High
2.101
Low
1.8971
52 wk Range
0.82-3.79
Market Cap
17 494 K
Shares Outstanding
8 451 K
EPS
-0.7
Beta
0.737
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Biovie Inc data using free add-ons & libraries
Get Biovie Inc Fundamental Data
Biovie Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -22 473 392
- Earnings Per Share: -3
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-12
- EPS/Forecast: -0.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Biovie Inc News
New
Biotech Stocks At 52-Week Highs - BIVI +22%, XNCR, ANRO, HAE, ACAD
(RTTNews) - The following biotech stocks reached a 52-week high on August 12, 2026, driven up by key catalysts such as positive quarterly reports or promising results from clinical trials. BioVie Inc...
Pre-Market Movers: BYAH, LXEO, ELTX Swing Big
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday. Price swings ahead of the opening bell are being driven by clinical trial and regulatory updates, as well as tria...
Dow, Nasdaq close lower as Treasury yields hit fresh highs
4:20pm: S&P 500 retreats for third straight session Stocks closed lower for a third straight session on Tuesday as rising Treasury yields and lingering inflation concerns continued to pressure equit...
Bench International Announces Appointment of Jim Lang to the Board of Directors of Halozyme Therapeutics
Appointment Strengthens Halozyme's Board as the Company Advances Its Global Drug Delivery Platform SAN DIEGO, Dec. 17, 2025 /PRNewswire/ -- Bench International today announced the appointment of Jim�...
Get Biovie Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
